2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD20

CD20

CD20 is a 33-37 kDa non-glycosylated protein expressed specifically on the surface of normal and malignant B lymphocytes, and belongs to the MS4A (membrane-spanning 4-domain family A) protein family. CD20 is a general B-cell marker expressed by the majority of B cells starting from late pre-B lymphocytes (it is not expressed by pro-B lymphocytes), and its expression is lost in terminally differentiated plasmablasts and plasma cells. Early experiments suggested that it was important in the regulation of human B-cell activation, proliferation, and Ca2+ transport. However, CD20-deficient mice appeared normal. Hence, the exact biological function of CD20 and its physiological ligand remain to be fully defined.240 Regardless of the uncertainty in the biological role of this antigen, it is a good target for cancer immunotherapy.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99776
    Plamotamab
    		Inhibitor 99.12%
    Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo.
    Plamotamab
  • HY-P99308
    Ocaratuzumab
    		Inhibitor
    Ocaratuzumab (AME 133v) is an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, with a Kd of ~100 pM. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC).
    Ocaratuzumab
  • HY-P991225
    BI-1206
    BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL).
    BI-1206
  • HY-P99952
    Ripertamab
    		Inhibitor
    Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL).
    Ripertamab
  • HY-P99855
    Divozilimab
    		Inhibitor 99.63%
    Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research.
    Divozilimab
  • HY-P990054
    Eramkafusp Alfa
    Eramkafusp Alfa is a human IgG1 antibody targeting the mouse B lymphocyte CD20 antigen MS4A1.
    Eramkafusp Alfa
  • HY-P990649
    PF-5212374
    		Inhibitor
    PF-5212374 (TRU-015) is a humanized antibody expressed in CHO, targeting CD20/MS4A1. PF-5212374 exhibits potent direct signaling and antibody-dependent cellular cytotoxicity, with complement-mediated cytotoxicity lower than that of Rituximab (HY-P9913). PF-5212374 has antitumor activity and can be used in the research of tumors such as lymphoma and inflammatory diseases.
    PF-5212374
  • HY-P991905
    AL044
    		Modulator
    AL044 is an antibody targeting MS4A family proteins. AL044 can mimic the protective effects of MS4A gene variants, thereby increasing the expression of both sTREM2 and membrane-bound TREM2 in cells. AL044 is applicable for research on Alzheimer's disease.
    AL044
  • HY-P991671
    Anafiltamig
    		Inhibitor
    Anafiltamig is a trivalent monoclonal antibody inhibitor targeting CD79B, CD3E and MS4A1. Anafiltamig consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv-based arm targeting CD3E and MS4A1. Anafiltamig simultaneously bridges T and B cells, activating T cells and specifically killing B cell tumors. Anafiltamig can be used for B cell malignancies such as non-Hodgkin lymphoma research.
    Anafiltamig
  • HY-P991547
    Anti-CD20 Antibody (mAb 1.5.3)
    Anti-CD20 Antibody (mAb 1.5.3) is a fully human IgG1 anti-CD20 antibody. Anti-CD20 Antibody (mAb 1.5.3) evokes enhanced pro-apoptotic activity in vitro. Anti-CD20 Antibody (mAb 1.5.3) mediated both complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Anti-CD20 Antibody (mAb 1.5.3) demonstrates enhanced anti-tumor activity in various tumor xenograft models. Anti-CD20 Antibody (mAb 1.5.3) produces a superior B-cell depletion profile in lymph node organs and bone marrow in a primate pharmacodynamic model. Anti-CD20 Antibody (mAb 1.5.3) can be studied in research for B-cell maglignancies.
    Anti-CD20 Antibody (mAb 1.5.3)
  • HY-P99660
    Imvotamab
    		Inhibitor
    Imvotamab (IGM-2323) is a CD20 and CD3 bispecific IGM antibody with dual action mechanism. Imvotamab is used to induce physiological T cell activation to prevent over-stimulation and subsequent down-regulation of immune function. Imvotamab can be used for the study of B-cell malignant tumors, multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL).
    Imvotamab
  • HY-P991548
    BLX-301
    		Inhibitor
    BLX-301 is a humanized monoclonal antibody targeting CD20. BLX-301 exhibits anti-tumor activity and can be used in the research of diseases such as non-Hodgkin lymphoma and rheumatoid arthritis.
    BLX-301
  • HY-P992349
    DXL625
    		Inhibitor
    DXL625 is an autophilic CD20-targeting agent. DXL625 triggers downstream apoptosis signaling pathways dependent on intact lipid rafts and extracellular Ca2+. DXL625 induces caspase-mediated apoptosis in cancer cells and selectively targets cells in the actively proliferative S phase. DXL625 mediates complement-dependent cytotoxicity in cancer cells and primary B lymphocytes. DXL625 can be used in research related to Burkitt's lymphoma and B-cell lymphoma.
    DXL625
  • HY-P991514A
    MIL62 (FUT8-KO)
    		Inhibitor
    MIL62 (FUT8-KO) is a CD20-targeting antibody that prepared by knocking out the fucosyltransferase 8 gene (FUT8) to remove fucose and thereby enhance the ADCC activity of the antibody.
    MIL62 (FUT8-KO)
  • HY-P992060
    Anti-Mouse CD20 Antibody (18B12)
    		Antagonist
    Anti-Mouse CD20 Antibody (18B12) is a B cell depleting agent that targets mouse CD20. Anti-Mouse CD20 Antibody (18B12) not only inhibits the growth of mesothelioma, lung cancer and thymoma, but also significantly enhances the efficacy of adenoviral tumor antigen vaccines and induces tumor regression by increasing the number of tumor-specific CD8+ T cells. Anti-Mouse CD20 Antibody (18B12) reduces B cell infiltration into the central nervous system of mice with experimental autoimmune encephalomyelitis, and delays motor dysfunction and neuronal death after spinal cord injury by alleviating inflammatory responses and tissue damage. Anti-Mouse CD20 Antibody (18B12) is widely applicable to research in fields related to mesothelioma, lung cancer, thymoma, experimental autoimmune encephalomyelitis and spinal cord injury.
    Anti-Mouse CD20 Antibody (18B12)
  • HY-P992144
    Zareprumig
    		Inhibitor
    Zareprumig is a human monoclonal antibody targeting CD20/MS4A1&CD71/TFRC.
    Zareprumig
  • HY-P991546
    MEDI-552
    		Inhibitor
    MEDI-552 is a human IgG monoclonal antibody targeting CD20/membrane-spanning 4-domains subfamily A member 1 (MS4A1).
    MEDI-552
  • HY-P991902
    NAV006
    		Inhibitor
    NAV006 is an anti-CD20 antibody variant of Rituximab (HY-P9913) with a Kd of 30.5 nM to CD20. NAV006 exhibits reduced interaction with CA125 and demonstrates enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activity. NAV006 displays antitumor activity against lymphoma and can be used in research on non-Hodgkin lymphoma.
    NAV006
  • HY-P992417
    MT-3724
    		Modulator
    MT-3724 is a CD20-targeted endotoxin B. MT-3724 binds to CD20, triggers receptor internalization, traffics to the endoplasmic reticulum, and induces permanent ribosomal inactivation to mediate cell killing. MT-3724 can inhibit protein synthesis and promote tumor cell apoptosis. MT-3724 can be used for the research of relapsed or refractory B-cell non-Hodgkin’s lymphomas and diffuse large B-cell lymphoma.
    MT-3724
  • HY-P992074
    Zemlikafusp alfa
    		Ligand
    Zemlikafusp alfa (IPH6501) is a tetra-specific NK cell engager that targets CD20, CD16a, NKp46 and carries an IL-2 variant. Zemlikafusp alfa (IPH6501) is used in research for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
    Zemlikafusp alfa
Cat. No. Product Name / Synonyms Application Reactivity